Literature DB >> 28559257

Etest and Sensititre YeastOne Susceptibility Testing of Echinocandins against Candida Species from a Single Center in Austria.

Maria Aigner1, Thomas Erbeznik2, Martin Gschwentner2, Cornelia Lass-Flörl2.   

Abstract

Candida species were tested for susceptibility to caspofungin, anidulafungin, and micafungin in order to evaluate the roles of Etest and Sensititre YeastOne in antifungal susceptibility testing for daily routines and to survey resistance. A total of 104 Candida species isolates detected from blood cultures were investigated. With EUCAST broth microdilution as the reference method, essential agreement (EA), categorical agreement (CA), very major errors (VME), major errors (ME), and minor (MIN) errors were assessed by reading MICs at 18, 24, and 48 h. By use of EUCAST broth microdilution and species-specific clinical breakpoints (CBPs), echinocandin resistance was not detected during the study period. Using EUCAST CBPs, MIC readings at 24 h for the Etest and Sensititre YeastOne resulted in CA levels of 99% and 93% for anidulafungin and 99% and 97% for micafungin. Using revised CLSI CBPs for caspofungin, CA levels were 92% and 99% for Etest and Sensititre YeastOne. The Etest proved an excellent, easy-to-handle alternative method for testing susceptibility to anidulafungin and micafungin. Due to misclassifications, the Etest is less suitable for testing susceptibility to caspofungin (8% of isolates falsely tested resistant). The CA levels of Sensititre YeastOne were 93% and 97% for anidulafungin and micafungin (24 h) by use of EUCAST CBPs and increased to 100% for both antifungals if CLSI CBPs were applied and to 100% and 99% if Sensititre YeastOne epidemiological cutoff values (ECOFFs) were applied. No one echinocandin could be demonstrated to be superior to another in vitro Since resistance was lacking among our Candida isolates, we cannot derive any recommendation from accurate resistance detection by the Etest and Sensititre YeastOne.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Candida species; Etest; Sensititre YeastOne; antifungal susceptibility testing; echinocandins

Mesh:

Substances:

Year:  2017        PMID: 28559257      PMCID: PMC5527638          DOI: 10.1128/AAC.00512-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.

Authors:  M A Pfaller; M Castanheira; S R Lockhart; A M Ahlquist; S A Messer; R N Jones
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

2.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

3.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.

Authors:  O A Cornely; M Bassetti; T Calandra; J Garbino; B J Kullberg; O Lortholary; W Meersseman; M Akova; M C Arendrup; S Arikan-Akdagli; J Bille; E Castagnola; M Cuenca-Estrella; J P Donnelly; A H Groll; R Herbrecht; W W Hope; H E Jensen; C Lass-Flörl; G Petrikkos; M D Richardson; E Roilides; P E Verweij; C Viscoli; A J Ullmann
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

4.  Intra- and Interlaboratory Agreement in Assessing the In Vitro Activity of Micafungin against Common and Rare Candida Species with the EUCAST, CLSI, and Etest Methods.

Authors:  J Meletiadis; E Geertsen; I Curfs-Breuker; J F Meis; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

5.  Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method.

Authors:  A Espinel-Ingroff; M Alvarez-Fernandez; E Cantón; P L Carver; S C-A Chen; G Eschenauer; D L Getsinger; G M Gonzalez; N P Govender; A Grancini; K E Hanson; S E Kidd; K Klinker; C J Kubin; J V Kus; S R Lockhart; J Meletiadis; A J Morris; T Pelaez; G Quindós; M Rodriguez-Iglesias; F Sánchez-Reus; S Shoham; N L Wengenack; N Borrell Solé; J Echeverria; J Esperalba; E Gómez-G de la Pedrosa; I García García; M J Linares; F Marco; P Merino; J Pemán; L Pérez Del Molino; E Roselló Mayans; C Rubio Calvo; M Ruiz Pérez de Pipaon; G Yagüe; G Garcia-Effron; J Guinea; D S Perlin; M Sanguinetti; R Shields; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

6.  Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.

Authors:  M A Ghannoum; A Chen; M Buhari; J Chandra; P K Mukherjee; D Baxa; A Golembieski; J A Vazquez
Journal:  Clin Microbiol Infect       Date:  2009-02-05       Impact factor: 8.067

7.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

8.  Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints.

Authors:  Maiken Cavling Arendrup; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191

9.  Multistate point-prevalence survey of health care-associated infections.

Authors:  Shelley S Magill; Jonathan R Edwards; Wendy Bamberg; Zintars G Beldavs; Ghinwa Dumyati; Marion A Kainer; Ruth Lynfield; Meghan Maloney; Laura McAllister-Hollod; Joelle Nadle; Susan M Ray; Deborah L Thompson; Lucy E Wilson; Scott K Fridkin
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

10.  Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study.

Authors:  José-Artur Paiva; José Manuel Pereira; Alexis Tabah; Adam Mikstacki; Frederico Bruzzi de Carvalho; Despoina Koulenti; Stéphane Ruckly; Nahit Çakar; Benoit Misset; George Dimopoulos; Massimo Antonelli; Jordi Rello; Xiaochun Ma; Barbara Tamowicz; Jean-François Timsit
Journal:  Crit Care       Date:  2016-03-09       Impact factor: 9.097

View more
  9 in total

1.  How Yeast Antifungal Resistance Gene Analysis Is Essential to Validate Antifungal Susceptibility Testing Systems.

Authors:  Nicolas Pellaton; Dominique Sanglard; Frederic Lamoth; Alix T Coste
Journal:  Front Cell Infect Microbiol       Date:  2022-05-04       Impact factor: 6.073

2.  Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.

Authors:  J M Boonstra; K C van der Elst; A Veringa; E M Jongedijk; R J Brüggemann; R A Koster; G A Kampinga; J G Kosterink; T S van der Werf; J G Zijlstra; D J Touw; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

3.  Antifungal Susceptibility of Clinical Yeast Isolates from a Large Canadian Reference Laboratory and Application of Whole-Genome Sequence Analysis To Elucidate Mechanisms of Acquired Resistance.

Authors:  Lisa R McTaggart; Ana Cabrera; Kirby Cronin; Julianne V Kus
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

4.  A nationwide passive surveillance on fungal infections shows a low burden of azole resistance in molds and yeasts in Tyrol, Austria.

Authors:  Cornelia Lass-Flörl; Astrid Mayr; Maria Aigner; Michaela Lackner; Dorothea Orth-Höller
Journal:  Infection       Date:  2018-07-03       Impact factor: 3.553

5.  Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia.

Authors:  Erika Lindberg; Helena Hammarström; Nasser Ataollahy; Nahid Kondori
Journal:  Sci Rep       Date:  2019-03-07       Impact factor: 4.379

6.  Antibacterial and Antifungal Activity of Propyl-Propane-Thiosulfinate and Propyl-Propane-Thiosulfonate, Two Organosulfur Compounds from Allium cepa: In Vitro Antimicrobial Effect via the Gas Phase.

Authors:  Antonio Sorlozano-Puerto; Maria Albertuz-Crespo; Isaac Lopez-Machado; Lidia Gil-Martinez; Juan Jose Ariza-Romero; Alba Maroto-Tello; Alberto Baños-Arjona; Jose Gutierrez-Fernandez
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-29

Review 7.  Diagnosis and Treatment of Invasive Candidiasis.

Authors:  Natalia Barantsevich; Elena Barantsevich
Journal:  Antibiotics (Basel)       Date:  2022-05-26

8.  Comparison of Two Commercial Colorimetric Broth Microdilution Tests for Candida Susceptibility Testing: Sensititre YeastOne versus MICRONAUT-AM.

Authors:  Sophie Philips; Frederik Van Hoecke; Emmanuel De Laere; Steven Vervaeke; Roos De Smedt; Jerina Boelens; Deborah De Geyter; Denis Piérard; Katrien Lagrou
Journal:  J Fungi (Basel)       Date:  2021-05-01

Review 9.  Susceptibility Testing of Fungi to Antifungal Drugs.

Authors:  Maurizio Sanguinetti; Brunella Posteraro
Journal:  J Fungi (Basel)       Date:  2018-09-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.